scholarly journals Modified PAMAM vehicles for effective TRAIL gene delivery to colon adenocarcinoma: in vitro and in vivo evaluation

2018 ◽  
Vol 46 (sup3) ◽  
pp. S503-S513 ◽  
Author(s):  
Elham Pishavar ◽  
Armin Attaranzadeh ◽  
Mona Alibolandi ◽  
Mohammad Ramezani ◽  
Maryam Hashemi
2021 ◽  
Vol 22 (8) ◽  
pp. 3828
Author(s):  
Laura Nicolle ◽  
Jens Casper ◽  
Melanie Willimann ◽  
Céline M. A. Journot ◽  
Pascal Detampel ◽  
...  

There is an increasing interest in cationic polymers as important constituents of non-viral gene delivery vectors. In the present study, we developed a versatile synthetic route for the production of covalent polymeric conjugates consisting of water-soluble depolymerized chitosan (dCS; MW 6–9 kDa) and low molecular weight polyethylenimine (PEI; 2.5 kDa linear, 1.8 kDa branched). dCS-PEI derivatives were evaluated based on their physicochemical properties, including purity, covalent bonding, solubility in aqueous media, ability for DNA condensation, and colloidal stability of the resulting polyplexes. They were complexed with non-integrating DNA vectors coding for reporter genes by simple admixing and assessed in vitro using liver-derived HuH-7 cells for their transfection efficiency and cytotoxicity. Using a rational screening cascade, a lead compound was selected (dCS-Suc-LPEI-14) displaying the best balance of biocompatibility, cytotoxicity, and transfection efficiency. Scale-up and in vivo evaluation in wild-type mice allowed for a direct comparison with a commercially available non-viral delivery vector (in vivo-jetPEI). Hepatic expression of the reporter gene luciferase resulted in liver-specific bioluminescence, upon intrabiliary infusion of the chitosan-based polyplexes, which exceeded the signal of the in vivo jetPEI reference formulation by a factor of 10. We conclude that the novel chitosan-derivative dCS-Suc-LPEI-14 shows promise and potential as an efficient polymeric conjugate for non-viral in vivo gene therapy.


2013 ◽  
Vol 50 (3-4) ◽  
pp. 484-491 ◽  
Author(s):  
Diego Delgado ◽  
Ana del Pozo-Rodríguez ◽  
M. Angeles Solinís ◽  
Artur Bartkowiak ◽  
Alicia Rodríguez-Gascón

2015 ◽  
Vol 233 ◽  
pp. 81-94 ◽  
Author(s):  
Neetinkumar D. Reddy ◽  
M.H. Shoja ◽  
B.S. Jayashree ◽  
Pawan G. Nayak ◽  
Nitesh Kumar ◽  
...  

2011 ◽  
pp. 110318075825099 ◽  
Author(s):  
Yufeng Zhang ◽  
Wei Fan ◽  
Luke Nothdurft ◽  
Chengtie Wu ◽  
Yinghong Zhou ◽  
...  

2010 ◽  
Vol 11 (4) ◽  
pp. 927-933 ◽  
Author(s):  
Yongxin Yang ◽  
Zhiwen Zhang ◽  
Lingli Chen ◽  
Wangwen Gu ◽  
Yaping Li

2012 ◽  
Vol 30 (5) ◽  
pp. 1215-1227 ◽  
Author(s):  
Ying Fan ◽  
Jing Yao ◽  
Ronghui Du ◽  
Lin Hou ◽  
Jianping Zhou ◽  
...  

Planta Medica ◽  
2010 ◽  
Vol 76 (12) ◽  
Author(s):  
J Bauer ◽  
F Dehm ◽  
A Koeberle ◽  
F Pollastro ◽  
G Appendino ◽  
...  

1999 ◽  
Vol 38 (04) ◽  
pp. 115-119
Author(s):  
N. Oriuchi ◽  
S. Sugiyama ◽  
M. Kuroki ◽  
Y. Matsuoka ◽  
S. Tanada ◽  
...  

Summary Aim: The purpose of this study was to assess the potential for radioimmunodetection (RAID) of murine anti-carcinoembryonic antigen (CEA) monoclonal antibody (MAb) F33-104 labeled with technetium-99m (99m-Tc) by a reduction-mediated labeling method. Methods: The binding capacity of 99m-Tc-labeled anti-CEA MAb F33-104 with CEA by means of in vitro procedures such as immunoradiometric assay and cell binding assay and the biodistribution of 99m-Tc-labeled anti-CEA MAb F33-104 in normal nude mice and nude mice bearing human colon adenocarcinoma LS180 tumor were investigated and compared with 99m-Tc-labeled anti-CEA MAb BW431/26. Results: The in vitro binding rate of 99m-Tc-labeled anti-CEA MAb F33-104 with CEA in solution and attached to the cell membrane was significantly higher than 99m-Tclabeled anti-CEA MAb BW431/261 (31.4 ± 0.95% vs. 11.9 ± 0.55% at 100 ng/mL of soluble CEA, 83.5 ± 2.84% vs. 54.0 ± 2.54% at 107 of LS 180 cells). In vivo, accumulation of 99m-Tc-labeled anti-CEA MAb F33-104 was higher at 18 h postinjection than 99m-Tc-labeled anti-CEA MAb BW431/26 (20.1 ± 3.50% ID/g vs. 14.4 ± 3.30% ID/g). 99m-Tcactivity in the kidneys of nude mice bearing tumor was higher at 18 h postinjection than at 3 h (12.8 ± 2.10% ID/g vs. 8.01 ± 2.40% ID/g of 99m-Tc-labeled anti-CEA MAb F33-104, 10.7 ± 1.70% ID/g vs. 8.10 ± 1.75% ID/g of 99m-Tc-labeled anti-CEA MAb BW431/26). Conclusion: 99m-Tc-labeled anti-CEA MAb F33-104 is a potential novel agent for RAID of recurrent colorectal cancer.


Sign in / Sign up

Export Citation Format

Share Document